FA Reproductive Flashcards
Leuprolide Mechanism
GnRH analog with agonist properties when used in pulsatile fashion; antagonist properties when used in continuous fashion (downregulates GnRH receptor in pituitary → ↓ FSH/LH).
Leuprolide Use
Infertility (pulsatile), prostate cancer (continuous - use with flutamide), precocious puberty (continuous).
Leuprolide Toxicity
Antiandrogen, nausea, vomiting.
Estrogens
Ethinyl estradiol, DES, mestranol
Estrogen Mechanism
Bind estrogen receptors
Estrogen Use
Hypogonadism or ovarian failure, menstrual abnormalities, HRT in postmenopausal women; use in men with androgen-dependent prostate cancer.
Estrogen Toxicity
↑ risk of endometrial cancer, bleeding in postmenopausal women, clear cell adenocarcinoma of vagina in females exposed to DES in utero, ↑ risk of thrombi. Contraindications - ER + breast cancer, history of DVTs.
Selective estrogen receptor modulators (SERMs)
Clomiphene, Tamoxifen, Raloxifene
Clomiphene Mechanism
Antagonist at estrogen receptors in hypothalamus. Prevents normal feedback inhibition and ↑ release of LH and FSH from pituitary, which stimulates ovulation.
Clomiphene Use
Treatment of infertility due to anovulation (e.g., PCOS).
Clomiphene Toxicity
May cause hot flashes, ovarian enlargement, multiple simultaneous pregnancies, and visual disturbances.
Tamoxifen Mechanism
Antagonist on breast tissue; agonist at uterus, bone.
Tamoxifen Use
Primarily used to treat and prevent recurrence of ER + breast cancer.
Tamoxifen Toxicity
Associated with endometrial cancer, thromboembolic events.
Raloxifene Mechanism
Agonist on bone; antagonist at uterus.
Raloxifene Use
↓ resorption of bone → used to treat osteoporosis.
Raloxifene Toxicity
↑ risk of thromboembolic events
Anastrozole, Exemestane Mechanism
Aromatase inhibitors used in postmenopausal women with breast cancer
Anastrozole, Exemestane Use
Used in postmenopausal women with breast cancer
Hormone Replacement Therapy Use
Used for relief or prevention of menopausal symptoms (e.g., hot flashes, vaginal atrophy) and osteoporosis (↑ estrogen, ↓ osteoclast activity).